论文部分内容阅读
目的观察依达拉奉治疗急性脑梗死的疗效。方法将75例急性脑梗死患者随机分成治疗组和对照组,治疗组38例,对照组37例。两组均给予常规药物(血塞通、阿司匹林等)治疗,治疗组加用依达拉奉30mg加生理盐水100ml静脉滴注,2次/d,连续治疗14d。同时观察不良反应。结果治疗14d后两组CSS评分差异有统计学意义(P>0.05),治疗组总有效率为86.84%,对照组总有效率为67.57%,两组比较差异有统计学意义(P<0.05)。无严重的并发症发生。结论依达拉奉治疗急性期脑梗死效果显著,不良反应少,安全可靠。
Objective To observe the therapeutic effect of edaravone on acute cerebral infarction. Methods Seventy-five patients with acute cerebral infarction were randomly divided into treatment group and control group, with 38 cases in the treatment group and 37 cases in the control group. Both groups were given conventional drugs (Xuesaitong, aspirin, etc.) treatment, the treatment group with edaravone 30mg plus saline 100ml intravenous infusion, 2 times / d, continuous treatment 14d. Adverse reactions were observed at the same time. Results After 14 days of treatment, the CSS scores of the two groups were significantly different (P> 0.05). The total effective rate was 86.84% in the treatment group and 67.57% in the control group, with significant difference between the two groups (P <0.05) . No serious complications occurred. Conclusion Edaravone has a significant effect in treating acute cerebral infarction with few adverse reactions and is safe and reliable.